Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Lists Impurity-Free Valsartan And Other ARB Drugs

Executive Summary

In the wake of impurities being discovered in certain valsartan and other ARB drugs, the FDA has published a list of known nitrosamine-free examples of these medicines as part of ongoing efforts to address the issue.

You may also be interested in...



Alembic Gets Sartans Shot In Q2

The continuing sartans crisis and new product launches in US helped Alembic to post a strong Q2 performance, despite slowdown in other markets.

Alembic Q2 Gets Sartans Shot

Continuing sartans crisis, new product launches in US help Alembic post strong Q2 performance despite slowdown in other markets.

NDMA In Ranitidine Risks Rerun Of Sartans Crisis

Regulators in North America and Europe are reacting to the discovery of the impurity NMDA in ranitidine, just over a year after similar impurities in sartan products led to a slew of recalls and withdrawals around the world.

Related Content

Topics

UsernamePublicRestriction

Register

GB140242

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel